Research
Hormonal
Consumption of non-digestible oligosaccharides (NDO) may interact with lipid metabolism, potentially lowering serum triacylglycerols and cholesterol in hyperlipidaemic individuals.
If you have slightly high blood fats, consuming 10-18g of inulin or oligofructose daily for 8+ weeks may help lower triglycerides and insulin levels. Effects on cholesterol are less consistent and may require longer consumption.
LimitedConditionalLOW confidence
There are preliminary indications that inulin-type fructans interact with the functioning of lipid metabolism.
Why this rating
Evidence is 'preliminary' and mixed; some human studies show no effect, especially in normolipidaemic individuals.
Source
Functional food properties of non-digestible oligosaccharides: a consensus report from the ENDO project (DGXII AIRII-CT94-1095)
Jan Van Loo et al. · British Journal Of Nutrition · 1999
DOI 10.1017/s0007114599000252
narrative_reviewCited 494×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Consumption of non-digestible oligosaccharides (NDO), specifically inulin-type fructans, exerts a prebiotic effect by selectively stimulating the growth and activity of bifidobacteria and lactic acid bacteria in the human large intestine.Good
- Consumption of non-digestible oligosaccharides (NDO) improves bowel habit by increasing stool frequency and weight, providing relief from constipation.Good
- Consumption of inulin-type fructans shows promising evidence for increasing calcium absorption in humans, potentially reducing osteoporosis risk.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →